How does atorvastatin inhibit ldl production?

How does atorvastatin block cholesterol production in the liver?

Atorvastatin binds to HMG-CoA reductase, the enzyme that converts HMG-CoA into mevalonate, the first committed step in the cholesterol synthesis pathway. By occupying the enzyme’s active site, it lowers the liver’s internal cholesterol output. The cell senses the drop and increases LDL-receptor expression on its surface, pulling more LDL particles from the blood and further reducing circulating LDL levels.

Why does the liver respond by making more LDL receptors?

When hepatic cholesterol falls, sterol regulatory element-binding protein 2 (SREBP-2) moves to the nucleus and activates transcription of the LDL-receptor gene. The added receptors bind circulating LDL via apolipoprotein B-100 and internalize it, cutting plasma LDL by 20-60 % depending on dose.

Can other statins work the same way?

All statins share the same competitive inhibition of HMG-CoA reductase, yet they differ in potency, half-life, and tissue uptake. Atorvastatin is lipophilic and has a long half-life, allowing once-daily dosing and sustained enzyme suppression.

What happens if you stop taking atorvastatin?

Within days the enzyme activity rebounds, hepatic cholesterol rises, and LDL-receptor numbers fall. Plasma LDL can return to baseline within two to four weeks unless another lipid-lowering agent is substituted.

When does the patent for atorvastatin expire?

The original composition-of-matter patent expired in 2011, opening the market to generics. Secondary patents on specific formulations or salt forms have also lapsed, so multiple manufacturers now supply the drug at low cost.

Where can I find the latest patent and exclusivity data?

DrugPatentWatch.com maintains current records on atorvastatin patents, regulatory exclusivities, and generic entry dates.

[1] https://www.drugpatentwatch.com